ArticleThe pharmacogenomics journal2018

MTHFR, TS and XRCC1 genetic variants may affect survival in patients with myelodysplastic syndromes treated with supportive care or azacitidine.

G Visani et al.PubMed ↗Publisher ↗

No numbers read from the abstract.